The UCL Partners academic health science centre has appointed David Fish as managing director.

Professor Fish is currently medical director for specialist hospitals for University College London Hospitals foundation trust, and has been a professor of epilepsy and clinical neurophysiology at UCL since 2000. Last year he became chair of Monitor’s medical directors advisory group.

The centre, comprising University College London, Great Ormond Street Hospital for Children trust, Moorfields Eye Hospital foundation trust, the Royal Free Hampstead trust and UCLH foundation trust, has also appointed programme directors for each of its eight programme themes.

A managing director and six programme directors have been hired to the UCL Partners academic health science centre. The directors are:

  • Child health David Goldblatt, professor of vaccinology and immunology and head of the immunobiology unit at the UCL Institute of Child Health and consultant paediatric immunologist at Great Ormond Street.
  • Eyes and vision Peng Khaw, professor of glaucoma and ocular healing at the UCL Institute of Ophthalmology and consultant ophthalmic surgeon at Moorfields Eye Hospital foundation trust.
  • Immunology and transplantation Hans Stauss, clinical director of immunology, endocrinology and diabetes at the Royal Free Hospital trust.
  • Infectious diseases Deenan Pillay, head of the UCL research department of infection and honorary consultant medical virologist at UCLH.
  • Neurological disorders Alan Thompson, director of the UCL Institute of Neurology and consultant neurologist at the National Hospital for Neurology and Neurosurgery.
  • Women’s health Judith Stephenson, Margaret Pyke professor of sexual and reproductive health at the UCL Institute for Women’s Health.

UCL Partners chair Sir Cyril Chantler said: “We are delighted to announce the appointments of this group of highly qualified and skilled academics and clinicians.

“It is another key milestone for UCLP and means that we can move forward with our plans to focus attention on the disease themes we have identified, with the ultimate aim of translating advances in medical research into treatments that will benefit patients.”

Appointments for the cardiovascular and cancer programme directors are yet to be announced.